Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review

Humaira Shamim 1, 2, Marie Jean 3, Muaaz Umair 4, Pratyusha Muddaloor 4, Michelle Farinango 4, Akhil Ansary 5, 6, Amulya Dakka 4, Zahra Nazir 7, Chantelle T. White 8, Ahmad B. Habbal 9, Lubna Mohammed 4

1. Dermatology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Dermatology, College of Physicians and Surgeons Pakistan, Lahore, PAK. 3. Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 4. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 5. Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 6. Clinical Sciences, St. Martinus University Faculty of Medicine, Willemstad, CUM 7. Internal Medicine Clinical Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 8. Psychology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 9. Cardiology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Humaira Shamim, dr.homaira@gmail.com

Abstract

Metformin, a biguanide hypoglycemic agent that is safe and effective for treating acne in women with the polycystic ovarian syndrome (PCOS), has shown growing evidence of improving insulin resistance, hyperandrogenism, dyslipidemia, overall cardiovascular health, quality of life, psychological wellbeing, and general health outcomes. This study aims to identify and summarize the effects of metformin in patients with PCOS-associated acne. This systematic review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search was done on PubMed, PubMed Central, Cochrane, Google Scholar, and Science Direct databases from 2011 up to 23 February 2022. Randomized controlled trials (RCTs), cross-sectional studies, observational studies, literature reviews, systematic reviews, and meta-analyses published in English were selected. The data was extracted to a predefined template. Each study was individually checked by using a quality assessment. The initial search generated a total of 218 studies. Nine studies were included in the final selection: two RCTs, one hospital-based clinical trial, three cross-sectional studies, three systematic reviews with meta-analyses, and one narrative review. Metformin is generally effective and safe for improving PCOS-associated acne and the quality of life. More clinical trials are required to determine the indications for prescribing metformin in patients with PCOS-associated acne.

Keywords: polycystic ovarian syndrome, antiandrogen, hyperandrogenism, metformin, nodulocystic acne, acne

Introduction And Background

In 1935, Stain and Leventhal first described polycystic ovarian syndrome (PCOS) in a series of seven women who presented with bilateral cystic ovaries, amenorrhea, hirsutism, and obesity [1]. Rotterdam criteria have been used to diagnose PCOS over the last 10 years.

PCOS affects a considerable proportion of women, particularly South Asians residing in the United Kingdom [2-4]. Fifty-two percent of women residing in the Indian subcontinent have polycystic ovaries, the highest reported prevalence [5]. PCOS is associated with interference in reproductive hormones like luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen, and testosterone which result in menstrual cycle irregularities like oligomenorrhea or amenorrhea. Acne is the most common manifestation of hyperandrogenism among other cutaneous manifestations like acanthosis nigricans, androgenic alopecia, and hirsutism. Acne vulgaris, characterized by chronic inflammation of the pilosebaceous unit, is one of the most common skin diseases for routine dermatology outpatient visits among patients aged 15 to 40 years [6]. Hyperandrogenism should be considered in female patients with sudden onset of severe acne that is associated with hirsutism or irregular menstrual periods. It is a risk for reproductive complications like infertility or subfertility, metabolic complications, cardiovascular risks, and psychological disturbances, along with type 2 diabetes and endometrial dysplasia [7-8]. Metformin is a biguanide that is effective and safe for improving insulin resistance, menstrual cycle irregularities, acne, and symptoms of hyperandrogenism like hirsutism [9]. Metformin’s mechanism of action is still not clear. While it is known to be an insulin-sensitizing agent which acts by inhibiting gluconeogenesis and lipogenesis, thus enhancing glucose uptake in the liver, skeletal muscles, adipose tissue, and ovaries. Metformin also decreases ovarian androgen production by 20% to 25% [10].

The role of metformin in acne and PCOS has been mentioned in 11 RCTs and nine cohort studies. All are shown to describe the remarkable improvement of PCOS-associated acne, except for three studies [11-12].

How to cite this article
Shamim H, Jean M, Umair M, et al. (August 27, 2022) Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review. Cureus 14(8): e28462. DOI 10.7759/cureus.28462
PCOS has a genetic predisposition and other multifactorial causes which include neuroendocrine, lifestyle, environmental, and obesity.

Hyperandrogenism, insulin resistance, compensatory hyperinsulinemia, and an imbalanced ratio of LH to FSH produce a metabolic disturbance and affect the ovaries and endometrium [11]. The exact etiology is an enigma.

The management of PCOS is a multidisciplinary approach that includes modification of general lifestyle by endocrinologists, gynecologists, dermatologists, and psychologist consults. Patients with PCOS are commonly seen first by a dermatologist [11]. The underlying hyperandrogenism that characterizes polycystic ovarian syndrome clinically manifests also as hirsutism and menstrual irregularities. Metformin also leads to clinical improvement in PCOS-associated acne. The pathophysiology of acne vulgaris is related to chronic inflammation of pilosebaceous follicles, increased sebum secretion, and colonization of Propionibacterium acnes [11]. This study aims to explore the role of metformin in PCOS-associated acne.

Review

Materials and methods

This study is done using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) to design and describe the findings of this systematic review. Search strategy: A primary literature search was conducted using PubMed, Google Scholar, Cochrane, and Science Direct. Articles from the last 10 years on females with PCOS-associated acne aged 19 to 44 years treated with Metformin were selected if they also met the criteria, for example, full-text articles in English and conducted from 2011 up to 23 February 2022. Using the MeSH search function, the keywords "polycystic ovarian syndrome", "metformin", "hyperandrogenism", and "acne" were used.

The PubMed was explored with Medical Subjects Headings [MeSH] controlled vocabulary or search items as follows ‘Polycystic Ovary Syndrome/diet therapy’[MeSH] OR ‘Polycystic Ovary Syndrome/drug therapy’ [MeSH] OR ‘Polycystic Ovary Syndrome/metabolism’[MeSH] OR ‘Polycystic Ovary Syndrome/physiology’[MeSH] OR ‘Polycystic Ovary Syndrome/statistics and numerical data’ [MeSH] OR ‘Polycystic Ovary Syndrome/therapy’ [MeSH] OR PCOS AND ANDROGEN ANTAGONISTS’[ALL FIELDS] OR ‘ANDROGEN ANTAGONISTS’[MESH TERMS] OR ANTIANDROGENS [TEXT WORD] OR METFORMIN [TEXT WORD] OR HYPERANDROGENISM AND ACNE OR [‘acne vulgaris’] [MeSH Terms] OR acne vulgaris [Text Word] OR [‘polycystic ovary syndrome’] [MeSH Terms] OR NODULOCYSTIC ACNE OR polycystic ovarian syndrome [Text Word] We applied the Boolean method to combine the keywords and MeSH terms and synthesize a uniform through searching various databases.

A total of 218 articles were included, which included 190 from PubMed, 25 from Google Scholar, two from the Cochrane database, and one from ScienceDirect. PubMed included 190 articles after MeSH searching - 166 records were irrelevant, and eight duplications were removed. Finally, 14 reports were evaluated for eligibility and quality.

The inclusion and exclusion criteria used in this review are presented in Table 1 below.

| Inclusion criteria                              | Exclusion criteria |
|------------------------------------------------|-------------------|
| English language                               | The presence of any dermatological disease besides acne. The Presence of any systematic disease. Pregnancy and lactation. Females of non-reproductive age group. Acne due to other causes like the use of steroid hormones, antidepressants, or Alcohol. |
| Articles free full text                        | Animal studies. Non-English language articles Study Selection 218 articles from the last 10 years were taken into consideration, including traditional reviews, systematic reviews, meta-analyses, bibliography, books and documents, case reports, classical articles, clinical studies, clinical studies, and clinical trials. |
| Female patients of PCOS in reproductive (age: 19-44 years) | Two researchers independently screened all free text articles titles and abstracts to be included and extracted the relevant studies, animal studies, and articles not written in the English language were excluded. The two researchers resolved disagreements over eligibility by studying the study design, intervention implemented, outcome measured, and the relevance to our inclusion and exclusion criteria. The final decision on study selection was reached by discussion. |

TABLE 1: Inclusion and exclusion criteria.
Study quality appraisal

We studied each article separately for the potential risk of bias. A comprehensive analysis of quality was conducted. The systematic reviews and meta-analyses were subjected to assessment using the multiple systematic reviews (AMSTAR) 2 tool [12]. The clinical trials and randomized control trials (RCT) were critically evaluated with the Cochrane Risk of Bias 2 (RoB2) tool. Each study was scrutinized based on seven criteria to find potential biases. The Newcastle Ottawa Scale (NOS) was used to assess the quality of cohort studies [13]. Each criterion was scored as either high quality, low quality, or unclear. Initially, 218 articles over the last 10 years were identified through search terms across four literature databases.

The final 11 articles were short-listed, as mentioned in the PRISMA chart [14].

Figure 1 shows the PRISMA chart.

Discussion

Acne, hirsutism, androgenic alopecia, acanthosis nigricans, and seborrheic dermatitis are common cutaneous manifestations of PCOS. Insulin resistance plays a pivotal role in polycystic ovarian syndrome [15,16]. The biguanide metformin (N, N-dimethyl biguanide) is a hypoglycemic drug that improves insulin sensitivity, decreases insulin levels, and corrects ovarian and functional adrenal hyperandrogenism in PCOS. Metformin also leads to clinical improvement in PCOS-associated acne [17,18].

Dermatologists encounter acne vulgaris in patients of age groups ranging from 14 to 40 years of age [19-20]. Metformin decreases hepatic glucose output and increases glucose availability for muscles and adipose tissues by reducing insulin resistance. Other commonly used treatment modalities in acne vulgaris are oral tetracyclines, azithromycin, isotretinoin, and topical agents like benzoyl peroxide, adapalene, topical tretinoins, and miscellaneous other topical agents. In addition, hormonal imbalance plays a determining role in the clinical development of acne. Androgens increase sebum production by activating the activity of
sebaceous glands. Colonization of Propionibacterium acne plays a pivotal role in the pathogenesis of acne formation, which may present as papules, pustules, nodules, cysts, and scarring [21].

**Major sources of androgens**

Major sources of androgens are ovaries and adrenal glands. Ovaries produce androstenedione and testosterone. Adrenal glands produce dehydroepiandrosterone sulfate [DHEA], androstenedione, and testosterone [19]. Clinical assessment of acne is usually graded by using Acne Global Severity Scale.

The US FDA Acne Global Severity Scale categorizes acne according to the following five categories:

1) Clear, with no inflammatory signs. 2) Almost clear, with no more than one pustule or papule. 3) Mild, some non-inflammatory lesions with no more than a few papules or pustules but no evidence of any nodule. 4) Moderate, up to many non-inflammatory lesions, may have some inflammatory lesions but no more than one small nodule. 5) Severe, up to many non-inflammatory and inflammatory lesions, but no more than a few nodules.

Acne vulgaris is common in almost 80% of teenage females and may or may not be associated with PCOS. When acne vulgaris is associated with PCOS, the following changes in the serum may be seen.

**Hormonal serum analysis**

Raised DHEAS, raised total free testosterone, raised androstenedione, reduced sex hormone binding globulin SHBG, raised LH, raised FSH, raised serum prolactin, raised insulin, high insulin-like growth factor binding protein IGFBP-1 and insulin-like growth factor IGF-1.

**Psychological effects of PCOS**

Patients with PCOS likely suffer from a wide range of psychological problems like low self-esteem, mood swings, depression, anxiety, and even psychosis. In PCOS, acne and hirsutism are the most common markers of affecting the quality of life by worsening the emotional well-being of women [21].

**Cutaneous manifestations of PCOS**

The cutaneous features of PCOS are the first to develop clinically. Early diagnosis is possible by screening the suspected patients, and prompt treatment to reduce complications and improve quality of life. These cutaneous features, like acanthosis nigricans, are closely related to insulin resistance. The raised levels of insulin act through insulin-like growth factor receptors to cause acanthosis nigricans, a skin condition characterized by thick and dark velvety skin in the axilla, groins, neck, and frictional surfaces [20,21]. Hyperandrogenism has clinical cutaneous findings of acne, hirsutism, androgenic alopecia, and seborrhea.

**Reproductive and neoplastic complications**

Obesity, infertility, hirsutism, and acne negatively affect the quality of life of women with PCOS. This latter is characterized by amenorrhea or anovulation, which is associated with infertility. Among the other gynecological complications, miscarriage, endometrial hyperplasia, and endometrial carcinoma have been documented.

Raised LH levels are involved in the pathogenesis of PCOS as a result of increased pulse frequency of hypothalamic gonadotropin hormone (GnRH) or low levels of progesterone resulting from oligo- or anovulation [19,22]. These patients can develop subfertility or infertility. The altered FSH- to LH ratio stimulates the ovarian theca cells to produce androstenedione. High levels of insulin also play a key role in PCOS pathogenesis.

PCOS manifests as hyperinsulinemia and hyperandrogenism and raises the level of the luteinizing hormone LH [19,23]. This alters the normal pituitary ovarian axis, which leads to the clinical presentation of oligomenorrhea, infertility, obesity, hirsutism, acne, hypertension, and hyperlipidemia [22]. The use of metformin leads to significant improvement of hyperandrogenism and its clinical manifestations.

Figure 2 explains the etiology of PCOS [23].
Table 2 explains different diagnostic criteria of PCOS [23].

| NIH/NICH 1992 | ESHRE/ASRM (Rotterdam Criteria) 2004 | Androgen Excess Society 2006 |
|---------------|--------------------------------------|-------------------------------|
| Exclusion of other causes of androgen excess or related disorders includes all of the following: | Exclusion of other androgen excess or related disorder includes two of the following: | Exclusion of other androgen excess and related disorders include all of the following: |
| 1) Clinical or biochemical Hyperandrogenism | 1) Clinical or biochemical Hyperandrogenism | 1) Clinical or biochemical Hyperandrogenism |
| 2) Menstrual Dysfunction | 2) Oligo-ovulation or anovulation | 2) Ovarian dysfunction or polycystic ovaries |

**TABLE 2: Diagnostic criteria of PCOS.**

ESHRE/ASRM. European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine; NIH/NICHD National Institutes of Health/National Institute of Child Health and Human Disease

**Cardiovascular complications of PCOS**

Insulin is produced by the pancreas. It helps to maintain the blood sugar level within the normal range. Hyperinsulinemia is usually linked to type 2 diabetes mellitus. However, symptoms of hyperinsulinemia include sugar cravings, weight gain, anxiety, sweating, frequent hunger, and fatigue leading to hypoglycemia. Metformin helps in ameliorating the symptoms of hyperinsulinemia in patients with PCOS. Metformin is reported to decrease hepatic glucose output, thereby decreasing the insulin requirement [24]. Women with PCOS are prone to hypertension, coronary vascular disease, and ischemic vascular disease [24]. Along with other common comorbidities, young women with PCOS are at risk of early-onset acute coronary...
vascular disease and endothelial dysfunction [25].

Figure 3 demonstrates the effects of PCOS at different stages of life [26].

**Mechanism of action of metformin**

The exact mechanism is unclear. Metformin is proposed to act by inhibiting mitochondrial function [27]. Creating an adenine triphosphate-deficient environment causes an activation of adenine monophosphate-activated protein kinase (AMPK) and upregulation of catabolic metabolism. Metformin diminishes the proinflammatory response by inhibiting nuclear factor kappa B (NF-κB) through both liver-related AMPK dependent and independent pathways, thus suppressing the production of nitric oxide (NO), prostaglandin E2 (PGE2), and acute inflammatory markers like tumor necrosis factor-alpha, interleukin-1, interleukin-6 [28].

Table 3 explains the study synthesis.

| Sr. | Author | Year of publication | Journal published | Type of study | Number of female patients with PCOS/number of articles | Purpose of study | Results | Conclusion |
|-----|--------|---------------------|-------------------|---------------|-------------------------------------------------------|-----------------|---------|------------|
| 1   | Timothy h. Schmidt et al. [17] | 2016 | JAMA Dermatology | Retrospective cross-sectional study | 401 patients | To identify cutaneous findings in PCOS | Hirsutism, acanthosis nigricans, and acne were associated with cutaneous findings in PCOS. | PCOS association with acne, hirsutism, and multiple other skin conditions. |
TABLE 3: Study synthesis table.

| No. | Authors | Year | Journal | Study Design | Participants | Objective | Findings |
|-----|---------|------|---------|--------------|-------------|----------|---------|
| 2   | Lee et al. [18] | 2017 | Dermatology Online Journal | A systematic review trials with 144 patients included | as an adjuvant for the treatment of acne vulgaris. | Reduction in acne after 12 weeks of metformin use. | Treatment in the treatment of moderate to severe acne vulgaris. |
| 3   | G. Frank et al. [19] | 2018 | European Review for Medical and Pharmacological Sciences | Hospital-based clinical trial 110 patients with PCOS | To investigate the impact of hormonal and metabolic disorders of PCOS-associated acne vulgaris. | The severity of acne in PCOS is related to serum testosterone, DHEA (Dehydroandrosterone) and dihydrotestosterone sulfate DHEA. |
| 4   | M. Artani et al. [20] | 2018 | Cureus Journal of Medical Science | Cross-sectional study 50 women PCOS included. | To determine the effects of metformin in polycystic ovarian syndrome. | Metformin improved acne, menstrual irregularities, and hirsutism. |
| 5   | S. Mukamala et al. [21] | 2018 | Journal of Pakistan Association of the Dermatologist | A cross-sectional study 50 patients | To document various cutaneous manifestations in PCOS. | Acanthosis nigricans and acne are the most common cutaneous manifestation of PCOS. Acanthosis nigricans to be the most common cutaneous finding in PCOS. |
| 6   | Shipli Sharma et al. [22] | 2019 | J Clin Aesthet Dermatol | Original research hospital-based interventional longitudinal study. 40 patients | To evaluate the efficacy of metformin therapy in women with PCOS-associated acne in terms of acne load. | Using the disease severity index DSI acne severity was reduced with metformin. Suggested efficacy in PCOS. |
| 7   | Calvin Sung et al. [23] | 2020 | Journal of Drugs in Dermatology | A systematic review 26 articles were shortlisted | To assess evidence related to the use of metformin for treating primary cutaneous disorders. | Metformin is safe and efficacious in treating various cutaneous disorders, including acne and PCOS. Metformin is safe and efficacious in PCOS and multiple other dermatological conditions. |
| 8   | Donna Vine et al. [24] | 2021 | Journal of the Endocrine Society | Randomized control trial 38 patients | To determine the effect of 12 weeks of high dose fish oil and metformin with metabolic syndrome and PCOS. | Fish oil and metformin significantly lowered fasting plasma triglycerides. |
| 9   | J. Bulsara et al. [25] | 2021 | Elsevier Journal endocrinology and Metabolic Science | Literature review article | To compare the efficacy of metformin alone and metformin combined with myo-inositol plus d chiro-inositol in women with polycystic ovary syndrome. | 72 patients were randomly allocated into two groups combined treatment has better results than metformin alone in these patients. Combined therapy may have better results. |
| 10  | A. Bahadur et al. [26] | 2021 | Cureus Journal of Medical Science | Randomized controlled trial 72 patients | To compare the efficacy of metformin alone and metformin combined with myo-inositol plus d chiro-inositol in women with polycystic ovary syndrome. | Equal efficacy of longer-acting versus metformin formulation but long-acting formulations being superior. |
| 11  | Jane I et al. [27] | 2021 | Diabetes ther | A systematic review and meta-analysis | | |

**Tolerability of metformin and potential adverse effects**

Gastrointestinal disturbance is the most common adverse effect that limits patient compliance. Lactic
acidosis is rarely seen. Metformin is frequently prescribed by endocrinologists. Metformin helps patients with PCOS in weight reduction. It also helps with metabolic comorbidities like dyslipidemia. Metformin acts centrally via suppressing hypothalamic neurons potentially and growth differentiation factor GDF-15 by reducing neuropeptide Y or by reducing appetite stimulation. There is also the involvement of gut-based mechanisms that increase the secretion of glucagon-like peptide GLP-1. Metformin improves lipid profile by inhibiting the activity of lipid synthesis [29].

The dose of metformin ranges from 750 to 2000mg. Metformin also helps the induction of ovulation in patients with PCOS. The side effects of metformin include nausea, diarrhea, flatulence, abdominal pain, and bloating. The small intestine has a concentration of metformin 30 to 300 times notably higher than plasma concentration [30]. The intestinal collection can be the reason for gastrointestinal side effects.

Limitations
This review was limited by the types of papers found in the PubMed, Google Scholar, Cochrane, and Science Direct databases. Only papers in English from 2011 to 2021, and papers from Grey literature were excluded. The small number of articles directly studying the drug metformin in association with PCOS and small sample sizes.

Conclusions
Metformin can have promising results in patients with PCOS. It may also potentially have positive effects on the quality of life. Further clinical trials are necessary. This summary of metformin in acne patients with PCOS recommends adequate efficacy, a high index of safety, and good tolerance. Thus, metformin can have a beneficial role in PCOS-associated acne.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
Dr. Hassaan Tohid, Dr. Syeda Sidra Hasnain, Dr. Lubna Mohammed, and my family for their motivation.

References
1. Stein IF.: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935, 181-91.
2. Davis SR, Knight S, White V, Claridge C, Davis BJ, Bell R: Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecol Endocrinol. 2002, 16:445-6.
3. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Bai G: The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017, 8:96313-8. 10.18632/oncotarget.19180
4. Wijeyeratne CN, Balen AH, Barth JH, Belchetz PE: Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clin Endocrinol (Oxf). 2002, 57:545-50. 10.1046/j.1365-2265.2002.01605.x
5. Rodin DA, Razo G, Bland JM, Taylor K, Nussey SS: Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf). 1998, 49:91-9. 10.1046/j.1365-2265.1998.00492.x
6. Stern RS: Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol. 2000, 43:1042-8. 10.1067/mjd.2000.110901
7. El Hayek S, Bittar L, Hamdar LH, Mirza FG, Daoud G: Polycystic ovarian syndrome: an updated overview. Front Physiol. 2016, 7:124. 10.3389/fphys.2016.00124
8. Goodarzi MO, Dumesic DA, Chazenbalk G, Aziz R: Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011, 7:219-31. 10.1038/nrendo.2010.217
9. Kazerooni T, Dehghan-Koushkghazi M: Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003, 17:51-6. 10.1080/gye.17.1.51.56
10. Homberg R, Inslser V: Ovulation induction in perspective. Hum Reprod Update. 2002, 8:449-62. 10.1093/humupd/8.5.449
11. Sivayoganathan D, Muruthini D, Clarville JM, Balen AH: Full investigation of patients with polycystic ovary syndrome (PCOS) presenting to four different clinical specialties reveals significant differences and undiagnosed morbidity. Hum Fertil (Camb). 2011, 14:261-5. 10.3109/14647273.2011.632058
12. Shea BJ, Reeves BC, Wells G, et al.: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136/bmj.j4008
13. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS)
for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2013.

14. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71

15. Ramezani Tehrani F, Amiri M: Polycystic ovary syndrome in adolescents: Challenges in diagnosis and treatment. Int J Endocrinol Metab. 2019, 17:e91554. 10.5812/ijem.91554

16. Artani M, Iftikhar MF, Khan S: Effects of metformin on symptoms of polycystic ovarian syndrome among women of reproductive age. Cureus. 2018, 10:e5203. 10.7759/cureus.5203

17. Schmidt TH, Khanijow K, Cedars MI, et al.: Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol. 2016, 152:391-8. 10.1001/jamadermatol.2015.4498

18. Lee JR, Smith AD: Metformin as an adjunct therapy for the treatment of moderate to severe acne vulgaris . Dermatology Online Journal. 2017, 10.5070/D32311037242

19. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R: Androgen excess: Investigations and management. Best Pract Res Clin Obstet Gynaecol. 2016, 57:98-118. 10.1016/j.bpbgy.2016.05.003

20. Keen MA, Shah IH, Sheikh G: Cutaneous manifestations of polycystic ovary syndrome: A cross-sectional clinical study, Indian Dermatol Online J. 2017, 8:104-10. 10.4103/2229-5178.202275

21. Abusailik MA, Muhanna AM, Almustecess AM, Alhusainat AM, Bani Mustafa SM, Nawaiseh MB: Cutaneous manifestation of polycystic ovary syndrome. Dermatol Reports. 2021, 13:8799. 10.4081/dr.2021.8799

22. Zhu T, Cui J, Goodarzi MO: Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes. 2021, 70:627-37. 10.2337/db20-0800

23. Bulsara J, Patel P, Soni A, Acharya S: A review: Brief insight into polycystic ovarian syndrome. Endocrine and Metabolic Science. 2021. 10.1016/j.endmets.2021.100085

24. Cussons AJ, Watts GF, Mori TA, Stuckey BG: Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009, 94:5842-8. 10.1210/jc.2009-0870

25. Vine D, Proctor E, Weaver O, Ghosh M, Maximova K, Proctor S: A pilot trial: Fish oil and metformin effects on ApoB-remnants and triglycerides in women with polycystic ovary syndrome. J Endocr Soc. 2021, 5:bvab114. 10.1210/jendso/bvab114

26. Bellver J, Rodriguez-Tabernero L, Robles A, et al.: Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet. 2018, 55:25-59. 10.1007/s10815-017-1047-7

27. Bahadur A, Arora H, Ravi AK, et al.: Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with Myoinositol Plus D-Chiro-Inositol in women with polycystic ovary syndrome (PCOS): A randomized controlled trial. Cureus. 2021, 13:e15510. 10.7759/cureus.15510

28. Johnson NP: Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014, 2:56. 10.3978/j.issn.2305-5839.2014.04.15

29. Osibogun O, Ogumnoro O, Michos ED: Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020, 50:399-404. 10.1016/j.tcm.2019.08.010

30. Pernicova I, Korbonits M: Metformin—mode of action and clinical implications for diabetes and cancer . Nat Rev Endocrinol. 2014, 10:143-56. 10.1038/nrendo.2013.256